Bristol Myers Squibb BMY announced that it has obtained FDA approval for the label expansion of Opdivo (nivolumab) plus Yervoy (ipilimumab). The regulatory body approved Opdivo plus Yervoy as a ...

21% with chemo; median PFS was not reached with the combo in the first-line setting ... evaluating Opdivo plus Yervoy (n=354) vs. Opdivo monotherapy (n=353) in the all-lines setting and ...

Assessing the dual primary endpoint of PFS, the trial demonstrated that median PFS was not reached with Opdivo plus Yervoy and was 39.3 months with Opdivo monotherapy. PFS rates at 12, 24, and 36 ...

So collect your kids - or perhaps your dogs - and some empty Easter baskets for these opportunities to meet the Easter Bunny, hunt for eggs and treats, jump in a bounce house or even learn how to ...